National Medical Products Administration (NMPA)

organization

Last mentioned: Mar 19, 2026

Timeline

  1. Healthy China 2030 Deadline

    Target date for achieving major healthcare and biotech self-sufficiency milestones.

  2. Strategic Target

    Deadline for China to become the primary global exporter of medical technology standards.

  3. Official Launch

    President Xi Jinping unveils the 15th FYP at the National People's Congress.

  4. Leadership Mandate

    New policy shift explicitly targets global leadership over 'catching up' with Western tech.

  5. 15th FYP Drafting

    Central Committee reviews the initial draft of the 2026-2030 strategic plan.

  6. Patent Milestone

    China surpasses the US in total international patent filings for CRISPR and AI-drug discovery.

  7. 14th Five-Year Plan

    China emphasizes 'self-reliance' and domestic technology loops.

  8. 14th FYP Implementation

    Focus on 'Dual Circulation' and initial biotech innovation pivot.

Stories mentioning National Medical Products Administration (NMPA) 2

pharma Neutral

China's 15th Five-Year Plan: Xi's Vision for Biotech Sovereignty

President Xi Jinping’s 15th Five-Year Plan (2026-2030) positions biotechnology as a cornerstone of "New Quality Productive Forces," prioritizing domestic innovation and supply chain self-sufficiency. This strategic shift aims to decouple China’s life sciences sector from Western dependencies while accelerating the commercialization of cell and gene therapies.

2 sources
pharma Neutral

China Signals Global Dominance in Biotech via New Strategic Roadmap

China’s latest strategic roadmap shifts from a 'catch-up' posture to a mandate for global leadership in frontier technologies. This pivot places biotechnology and genomic medicine at the center of national security and economic growth, challenging decades of U.S. dominance in drug innovation.

2 sources